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p18, and Cnb1 will provide new insight into the control
of these critical selection events and their outcomes.
Winslow et al. (2006) also report significant decreases
in serum antibody later in the primary response and in
the memory response to antigen recall. These changes
indicate a diminution of long-lived plasma cells that are
another cellular product of the GC reaction. Therefore,
NFATc transcription may be involved in the initial com-
mitment to long-lived plasma cell fate or may influence
the expression of genes necessary for their survival long
term. Interestingly, the decreased memory response to
antigen recall also supports a role for NFATc transcrip-
tion in the production of memory B cells in the GC cycle.
It is possible that memory B cell fate relies on the dis-
crimination and integration of BCR signal strength,
and GC T cell help and differential NFATc transcription
may control this critical cell fate decision.
This powerful new model demonstrates the impact of
Cnb1 ablation on many facets of B cell responsiveness
in vivo. Primary B cell subset development is differen-
tially influenced with surprisingly no impact on the de-
velopment of B cell tolerance. TI and TD responses
are modified in a number of ways that reveal subtle
and substantial effects on the integration of BCR signals
in the determination of a variety of secondary B cell fate
decisions. The role of the calcineurin-NFAT pathway in
memory B cell development will certainly be important
to dissect more completely, and this new model pro-
vides a valuable new perspective to this endeavor.
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In this issue of Immunity, Lee et al. (2006) describe
a physical and functional relationship between Toll-
like receptor 3 (TLR3) and the pattern recognition pro-
tein CD14. In the presence of CD14, TLR3-mediated
signal transduction events are amplified.
CD14 has been known to be associated with TLRs for
many years. As a major lipopolysaccharide (LPS) bind-
ing protein, CD14 has a critical role in the mammalian
response to LPS. CD14 has also been demonstrated
to amplify many TLR2-specific responses. However,
many of us have assumed that in this ‘‘amplification’’
role, CD14, a glycosyl phosphadityl inositol anchored
protein, was interacting with TLR2 or TLR4 (both of
which are cell surface proteins) on the exterior mem-
brane of the cell. TLR3, on the other hand, which is ac-
tivated by double-stranded RNA, appears to function
primarily intracellularly (and is localized by Lee et al.
[2006] within the cell). This leads to a paradox. How
does an intracellular TLR such as TLR3 interact with
the extracellular pattern recognition protein CD14?The GPI-anchored pattern recognition protein CD14
was initially characterized as a major LPS binding
protein (reviewed in Ziegler-Heitbrock and Ulevitch
[1993]). Mice without CD14 do not develop shock in re-
sponse to LPS challenge. Furthermore, the administra-
tion of monoclonal antibodies to CD14 can prevent sep-
tic shock in humans as well as mice. Interestingly, CD14
is present as a soluble protein in large quantities in the
serum of humans (and mice). Although the GPI anchor
of membrane CD14 contributes to its ability to enhance
cellular response to LPS, particularly at low concentra-
tions of ligand, the GPI linkage is dispensable. Thus,
both soluble CD14 as well as the cell-associated GPI-
anchored protein are able to enhance the cellular cyto-
kine response to LPS (Underhill, 2003; Ziegler-Heitbrock
and Ulevitch, 1993). Further, a CD14 construct in which
the GPI anchor was replaced with a bilayer spanning
transmembrane region also enhances the response to
LPS (Pugin et al., 1998). This is of particular interest be-
cause only the GPI-linked form of CD14 has been dem-
onstrated to reside in cholesterol-rich lipid microdo-
mains that contain src kinases and G proteins, which
play important roles in the response to LPS (Lentschat
et al., 2005; Solomon et al., 1998). For those of us who
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128Figure 1. CD14 Is a Multifunctional Adapter
Protein
CD14 is a glycosylphosphatidlyinositol (GPI)-
anchored protein that is expressed on the
surface. It is associated with src family ki-
nases and heterotrimeric G proteins in lipid
rafts. CD14 can bind bacterial lipopolysac-
charide (LPS) and viruses on the cell surface.
CD14 interacts with various Toll-like recep-
tors (TLRs) to induce cytokines after virus or
bacterial infection. The TLR pathway subse-
quently induces cytokine production through
the adaptor proteins MyD88, Mal (also known
as TIRAP), and/or Trif and TRAM. CD14 can
also bind dsRNA intracellularly and interact
with TLR3, which is not expressed on the cell
surface.thought that the extracellular location of GPI-linked
CD14 was critical to its mechanism of activity as an
amplifier of signal transduction, this result came as
something of a surprise. It is now recognized that
CD14 enhances LPS responsiveness by binding LPS
and facilitating LPS transfer to Toll-like receptor
4-MD2 (TLR4-MD2), the signaling receptor complex
for LPS responses (Latz et al., 2002). Lee et al. (2006)
now demonstrate that CD14 also binds to poly I:C and
facilitates its association with TLR3 within endosomes
(Figure 1).
Although the role of CD14 in LPS responses is well
established, the contribution of CD14 to other TLR-
dependent ligands has been less well studied. In partic-
ular, it has been known for some time that CD14 contrib-
utes to the innate immune response activated by other
non-LPS ligands, including many TLR2 ligands (Pugin
et al., 1994). In addition to its role in bacterial pathogen-
esis where it interacts with TLR4, CD14 has been asso-
ciated with the cytokine response to respiratory syncy-
tial virus (RSV), cytomegalovirus (CMV), and influenza
virus (Compton et al., 2003; Kurt-Jones et al., 2000; Pau-
ligk et al., 2004). The absence of CD14, either by genetic
knockout in mice or simply the lack of a source of CD14
in the serum, leads to a decrease in the cytokine re-
sponse initiated by virus infection. In these studies,
CD14 is often thought of as a coreceptor that helps
bring the virus (or other ligand) to the signal transducing
receptor (the TLR). But viral ligands like the ssRNA of
influenza are expressed intracellularly. How could an
extracellular protein like CD14 interact with viral nucleic
acids (DNA, ssRNA, and dsRNA), which are produced
during the viral replication cycle inside the cells? How
could CD14 facilitate the cytokine response?
The study by Lee et al. (2006) in this issue of Immunity
may shed some light on these paradoxes. The authors
demonstrated that CD14 physically associates with
TLR3 within an intracellular compartment (likely within
the ER or in endosomes) and augments cytokine re-
sponses by TLR3 to a dsRNA ligand. Furthermore, using
labeled poly I:C (dsRNA), the authors demonstrate that
CD14 also binds to poly I:C, and that in turn, facilitates
uptake of poly I:C into an intracellular, possibly endoso-
mal, compartment. Here, CD14 facilitates signaltransduction and cytokine production by delivering poly
I:C to the signaling receptor TLR3.
But what is the mechanism by which CD14 amplifies
the TLR-specific responses? CD14, by virtue of its GPI
linkage, resides in lipid rafts (Schmitz and Orso, 2002).
These rafts contain src kinases and G protein signal
transduction molecules (Solomon et al., 1998). The ki-
nases in the rafts are themselves linked to lipids (e.g., du-
ally acylated) and thus concentrate in microdomains.
CD14 is in the outer membrane leaflet of the rafts,
whereas the src kinases and G proteins concentrate in
the inner leaflet of the rafts. It is possible that CD14, in ad-
dition to serving as a chaperone for LPS and other li-
gands, may serve as a matchmaker for src kinases and
components of the TLR signaling complex. CD14 inter-
acts with the N-terminal regions of the TLRs, whereas
the src kinases and G proteins interact with the C-termi-
nal TIR domain and adaptor proteins associated with
TLRs. Thus, CD14 may further enhance cytokine produc-
tion in response to poly I:C by directly associating with
TLR3 (e.g., in a poly I:C-TLR3-CD14 complex) and subse-
quently move the entire poly I:C-TLR3-CD14 complex
into the kinase and G protein-rich environment of lipid
rafts. Indeed, Lee et al. (2006) note that activated TLR3
complexes moved to less dense membrane fractions
consistent with lipid rafts after activation.
Based on the data of Lee et al., CD14 is capable of in-
teracting with TLR3 proteins within the cell: either in the
Golgi or the endoplasmic reticulum. Several other labs
studying TLR signal transduction and using coimmuno-
precipitation have shown that CD14 interacts directly
with TLR2 and TLR4 (Schmitz and Orso, 2002). This
is likely a dynamic, ligand-independent interaction
because CD14-TLR complexes are detected in the ab-
sence of exogenous LPS or other known TLR ligands.
Free CD14 is found in excess over CD14-TLR com-
plexes and is known to move freely in and out of cells
by export and retrograde transport through the Golgi
(Thieblemont and Wright, 1999). The delivery of ligands
to their appropriate TLR may stabilize the TLR-CD14 in-
teraction, because only ligand-activated TLR-CD14
complexes move into lipid rafts (Schmitz and Orso,
2002). These studies suggest that CD14 may act both
as a transporter of microbial ligands (delivering
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129activating molecules such as LPS and poly I:C to TLRs
both on the cell surface and within cells) and as a signal
amplifier by moving TLRs into kinase-rich environment
of lipid raft microdomains (Figure 1). These speculations
are not entirely without clinical importance as we and
others have shown that kinase inhibitors and G protein
binding reagents may affect the production of cytokines
mediated by these CD14-related pathways (Lentschat
et al., 2005; Solomon et al., 1998).
Why is the nature of the ‘‘amplifying’’ effect of CD14
important? CD14, like TLRs, is a polymorphic protein,
and single nucleotide polymorphisms of CD14 have
been shown to predict susceptibility or resistance to
a variety of diseases. Furthermore, we and others have
demonstrated that src kinase inhibitors and G protein
binders may modulate CD14-associated responses.
Drugs that modulate the function of CD14 are possible,
but we need to understand how they might work both
intracellularly and extracellularly. The exciting new
studies of Lee et al. (2006) suggest that therapies target-
ing CD14 may also interfere with TLR3 activation by viral
nucleic acids, thus holding out the prospect these
agents may be effective in the control of viral as well
as bacterial diseases in which excess immune respon-
siveness damages the host.
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An Unexpected Connection:
Lymph Node Lymphangiogenesis
and Dendritic Cell Migration
Migration of antigen-presenting dendritic cells (DCs)
through lymphatics to draining lymph nodes (LNs)
represents a key step in the initiation of an adaptive
immune response. In this issue of Immunity, Angeli
et al. (2006) provide the first evidence that remodeling
of the lymphatic network within LNs and in peripheral
tissues enhances DC migration after immunization
and that this process depends on the presence of B
cells within the LN.
For decades, the lymphatic vascular system has been
considered as a rather inert drainage system of the body,
primarily involved in transporting protein-rich fluid
and leukocytes from peripheral tissues to LNs and back
to the blood circulation. Only over the last years has
it become apparent that lymphatic vessels are actively
involved in many physiologic and pathologic pro-
cesses (Oliver and Detmar, 2002). In particular, remod-
eling of the lymphatic system by tumor-derivedSelected Reading
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lymphangiogenic factors actively promotes cancer me-
tastasis, and lymphangiogenesis also plays a major role
in the pathogenesis of various inflammatory conditions
(Alitalo et al., 2005). Recent studies have revealed
a close relationship between lymphangiogenesis and
immunity: inflammatory cells such as macrophages
produce lymphangiogenic factors (Cursiefen et al.,
2004) and might physically contribute to lymphatic ves-
sel formation (Maruyama et al., 2005). Furthermore, kid-
ney transplant rejection is frequently accompanied by
lymphangiogenesis (Kerjaschki et al., 2004), and the
chronic autoimmune disease psoriasis is characterized
by extensive lymphatic hyperplasia (Kunstfeld et al.,
2004). Although migration of antigen-presenting DCs
through lymphatics to draining LNs is an important step
in the initiation of an adaptive immune response, very lit-
tle is known about how lymphangiogenesis affects DC
migration.
In this issue of Immunity, Angeli et al. (2006) provide
the first evidence that remodeling of the lymphatic net-
work within the LN and in peripheral tissues enhances
DC migration to the draining LN after immunization with
complete Freund’s adjuvant (CFA). Surprisingly, the au-
thors find that, in mice, DC migration is not only en-
hanced from the local site of adjuvant injection into
